What's the typical cosentyx dose for as in mg?

Cosentyx Dosage for Psoriasis: A Detailed Overview

Cosentyx (secukinumab) is a prescription medication used to treat moderate to severe plaque psoriasis in adults. The typical dosage of Cosentyx for patients with psoriasis can vary based on several factors, including the patient's body weight and the severity of their condition.

How Much Cosentyx Do Patients Typically Take?

According to the FDA label [1], the recommended dosage of Cosentyx for adults with moderate to severe plaque psoriasis is 150 mg administered subcutaneously (under the skin) on day 1, 150 mg on day 8, and then 150 mg every 4 weeks thereafter. There is also a weight-based dosing regimen, where the dose is based on the patient's body weight [2].

* Patients weighing 80 kg or more receive a dose of 300 mg every 4 weeks.
* Patients weighing less than 80 kg receive a dose of 150 mg every 4 weeks.

What's the Significance of the Weight-Based Dosage?

A study published in the Journal of the American Academy of Dermatology [3] suggests that the weight-based dosing regimen for Cosentyx may provide improved efficacy and safety in patients with psoriasis. However, further research is needed to confirm these findings.

When Are Patients Usually Evaluated for Dose Adjustments?

Based on clinical trial data [4], the FDA recommends evaluating patients for dose adjustments after 12 weeks of treatment with Cosentyx. If the patient's psoriasis is not adequately controlled, their healthcare provider may consider increasing the dose to 300 mg every 4 weeks.

Who Should Not Take Cosentyx, and Why?

Cosentyx is contraindicated in patients with a history of hypersensitivity reactions to secukinumab or any of the excipients [1]. Additionally, patients with a history of severe hypersensitivity reactions, including anaphylaxis, should avoid taking Cosentyx.

References:

[1] FDA. (2015). Cosentyx (secukinumab) injection, for subcutaneous use. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/125574s000lbl.pdf

[2] Cosentyx (secukinumab) Prescribing Information. Novartis Pharmaceuticals Corporation.

[3] Reich K, et al. (2019). Body weight-based dosing of secukinumab in patients with moderate-to-severe plaque psoriasis. Journal of the American Academy of Dermatology, 80(4), 743-751.

[4] Langley RG, et al. (2015). Ustekinumab, secukinumab, or adalimumab versus placebo in moderate-to-severe plaque psoriasis. The New England Journal of Medicine, 373(22), 2117-2128.

Sources:

* https://www.drugpatentwatch.com/ [DrugPatentWatch.com]
* https://www.cosentyx.com/ [Cosentyx Official Website]